IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

FARINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.833
NA - Nord America 5.403
AS - Asia 5.174
SA - Sud America 534
AF - Africa 130
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 10
Totale 17.104
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.178
CN - Cina 1.650
SG - Singapore 1.579
GB - Regno Unito 1.521
IT - Italia 946
DE - Germania 733
SE - Svezia 698
RU - Federazione Russa 511
HK - Hong Kong 474
BR - Brasile 396
NL - Olanda 288
IN - India 287
FR - Francia 278
BD - Bangladesh 258
VN - Vietnam 255
TR - Turchia 216
UA - Ucraina 207
CA - Canada 157
IE - Irlanda 148
KR - Corea 148
FI - Finlandia 146
EU - Europa 118
PL - Polonia 100
ID - Indonesia 62
JP - Giappone 61
CO - Colombia 56
CI - Costa d'Avorio 53
BE - Belgio 41
MX - Messico 40
GR - Grecia 39
AR - Argentina 32
ES - Italia 32
DK - Danimarca 27
IQ - Iraq 24
CH - Svizzera 22
PH - Filippine 22
RO - Romania 22
ZA - Sudafrica 20
AU - Australia 15
AT - Austria 14
TW - Taiwan 14
IR - Iran 13
MY - Malesia 13
PK - Pakistan 13
UZ - Uzbekistan 13
IL - Israele 12
MA - Marocco 12
PY - Paraguay 11
EG - Egitto 10
CL - Cile 9
KE - Kenya 9
EC - Ecuador 8
PE - Perù 8
SA - Arabia Saudita 8
AL - Albania 7
JM - Giamaica 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
CZ - Repubblica Ceca 6
JO - Giordania 6
NO - Norvegia 6
TH - Thailandia 6
AZ - Azerbaigian 5
LB - Libano 5
LT - Lituania 5
NZ - Nuova Zelanda 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
BG - Bulgaria 4
CR - Costa Rica 4
DZ - Algeria 4
HR - Croazia 4
KZ - Kazakistan 4
LU - Lussemburgo 4
NP - Nepal 4
PS - Palestinian Territory 4
PT - Portogallo 4
SI - Slovenia 4
UY - Uruguay 4
BH - Bahrain 3
BO - Bolivia 3
HN - Honduras 3
SC - Seychelles 3
XK - ???statistics.table.value.countryCode.XK??? 3
CG - Congo 2
CY - Cipro 2
ET - Etiopia 2
GT - Guatemala 2
KG - Kirghizistan 2
LV - Lettonia 2
LY - Libia 2
NG - Nigeria 2
PA - Panama 2
RS - Serbia 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BM - Bermuda 1
Totale 17.197
Salva come PNG Salva come JPEG
Città #
Southend 1.356
Singapore 940
Ashburn 531
Hong Kong 453
Chandler 420
Beijing 376
San Jose 318
Milan 302
Seattle 248
Princeton 204
Dallas 193
Wilmington 193
Santa Clara 177
Council Bluffs 159
Frankfurt am Main 155
Los Angeles 154
Jacksonville 150
Dublin 144
Boardman 134
Ann Arbor 121
Mountain View 121
Bengaluru 112
Redmond 112
Nanjing 111
Fairfield 103
Moscow 92
Lauterbourg 91
Toronto 91
Warsaw 90
Munich 89
New York 88
Ho Chi Minh City 81
Phoenix 81
Shanghai 74
Sakarya 73
Buffalo 72
Woodbridge 72
Dearborn 66
Des Moines 62
Hanoi 59
Medford 56
Abidjan 53
Serra 53
Guangzhou 52
Helsinki 50
São Paulo 50
Andover 49
Hefei 49
Bogotá 46
Rome 46
Somerville 40
Tokyo 40
Shenyang 39
Jakarta 38
Tianjin 37
Cambridge 36
Houston 35
Athens 34
Jinan 34
Columbus 33
Brussels 32
Changsha 32
Nanchang 32
Redwood City 31
Eitensheim 30
Cangzhou 28
Chicago 26
London 26
San Diego 25
Sunnyvale 24
Berlin 23
Mumbai 23
Hamburg 21
Odernheim 21
The Dalles 21
Hangzhou 20
Hebei 20
Nuremberg 20
Zhengzhou 20
Hanover 19
Quanzhou 19
Bitonto 18
Fuzhou 18
Roxbury 18
Montreal 16
Turin 16
Da Nang 15
Ottawa 15
Seoul 15
Orem 14
Wuhan 14
Amsterdam 12
Grafing 12
Haikou 12
Naples 12
Falkenstein 11
Johannesburg 11
Kiez 11
Shenzhen 11
Boston 10
Totale 10.112
Salva come PNG Salva come JPEG
Nome #
Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy 383
Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle 362
CD133+ cells isolated from various sources and their role in future clinical perspective 352
Modificazione genica di cellule staminali distrofiche allo scopo di trapianto autologo nella distrofia muscolare di Duchenne 337
Preliminary evidences of safety and efficacy of flavonoids- and omega 3-based compound for muscular dystrophies treatment: a randomized double-blind placebo controlled pilot clinical trial. 312
Expression of CD20 reveals a new store-operated calcium entry modulator in skeletal muscle 287
T and b lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse 283
Exome sequencing identifies variants in two genes encoding the LIM-proteins NRAP and FHL1 in an Italian patient with BAG3 myofibrillar myopathy 273
Skin-derived stem cells transplanted into resorable guides provide functional nerve regeneration after sciatic nerve resection 258
Correlation of circulanting CD133+ progenitor subclasses with a Mild phenotype in Duchenne Muscular dystrophy patients 255
Characterization of muscle-specific expression of miRNAs in duchenne muscular dystrophy 251
Microbiota dysbiosis influences immune system and muscle pathophysiology of dystrophin‐deficient mice 249
Abundance of circulating progenitors with myo-endothelial potential correlates with a mild phenotype in patients affected by Duchenne muscular dystrophy 248
Stem cells and muscular dystrophies 246
Morphological modifications of resected sciatic nerve after autologous transplantation of skin-derived stem cells into resorable guides. 242
VCAM-1 expression on dystrophic muscle vessels has a critical role in the recruitment of human blood-derived CD133+ stem cells after intra-arterial transplantation 237
Combining Stem Cell and Exon Skipping Approach to Treat Muscular Dystrophies 235
CD20-related signaling pathway is differently activated in normal and dystrophic circulating CD133+ stem cells 229
Stem cell-mediated exon skipping of the dystrophin gene by the bystander effect 225
Impact of Muscular Dystrophy on the Regenerative Properties of interstitial Muscle Cells 224
Defective dystrophic thymus determines degenerative changes in skeletal muscle 222
Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model 221
Advancements in stem cells treatment of skeletal muscle wasting 221
Development of a new technique for muscle tissues-stem cells co-colture 209
Combining gene and stem cell therapy in the treatment of disferlinopaties 203
Perspectives of Stem Cell Therapy in Duchenne Muscular Dystrophy 202
MicroRNA-206 is upregulated in an animal model of Duchenne Muscular Distrophy 197
In Vivo Tracking of Stem cell by Nanotechnologies : Future Prospect for Mouse to Human Translation 197
Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model 196
Skin-derived stem cells transplanted into resorbable guides provide functional nerve regeneration after sciatic nerve resection 195
Cell Therapy of Muscular Dystrophy with Engineered CD133+ Cells 192
Cell Theraphy of Muscolar Dystrophy with Engineered CD133+Cell 192
MicroRNA-206 is upregulated in an animal model of Duchenne Muscular Distrophy. 191
Full-length dysferlin expression driven by engineered human dystrophic blood-derived CD133+ stem cells 191
Role of Insulin-Like Growth Factor Receptor 2 across Muscle Homeostasis: Implications for Treating Muscular Dystrophy 191
Development of new technologies Including myogenic differentiation of human circulating CD133+cells 190
Ex vivo expansion of human circulating CD133+ progenitors cells: promising tool for cell-based therapeutic approaches in muscular dystrophy. 188
Combining Gene and Stem Cell therapy in the Treatment of Dysferlinophaties 185
Differential Activativation of CD20-Related Signalling Pathway Results in Distinct Differentiation Behaviour of Normal and DMD Circulating CD133+ Stem Cells 182
Muscular dystrophies therapies by engineered stem cells 181
The myomiR-206 partecipate to muscle-regeneration by sculpting the chromatin through the down.regulation of the non-histone chromatin-associated protein High Mobility group protein 3 (Hmgb3) 180
Preclinical experience and perspectives of a clinical trial using cD133 stem cells 179
Cell Based Therapy for Duchenne Muscular Dystrophy 178
Muscle-specific microRNAs (mirnas) in Duchenne Muscular Distrophy (DMD). 178
Ex vivo expansion of human circulanting CD133+promising tool for cell-based therapeutic approaches in muscular dystrophy 177
Combining stem cells and exon skipping strategy to treat muscular dystrophy 177
The role of stem cells in muscular dystrophy 177
Ex vivo expansion of peripheral blood CD133+ progenitors cells: promising tool for cell-based therapeutic approaches in muscular dystrophy. 176
Exon-skipping of dysferlin in CD133+ stem cells isolated from normal and patient affected with dysferlinopathies. 174
Hmgb3 Is Regulated by MicroRNA-206 during Muscle Regeneration 174
Rescue of human dystrophin after transplantation of exon-skipping-engineered DMD stem cells in a dystrophic animal model 173
Stem Cell Therapies to Treat Muscular Dystrophy : Progress to Date 169
Proliferation and clonal characterization of human muscle derived CD133+ positive stem cells define an intrinsic heterogeneity 169
Proliferation and Clonal Analysis of Muscle Derived CD133+ Stem Cell Subpopulations Define a Depletion of Mesenchymal Population in DMD Patients 169
Absence of T and B lymphocytes enhances skeletal muscle regeneration and ameliorates dystrophic pathology in dysferlin deficient animal model 168
Autologous transplantation of engineered muscle-derived CD133+ stem cells 167
Myogenic differentiation potential of CD133+ stem cells isolated from various sources 167
In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled CD133+ stem cell tropism to dystrophic muscle tissues using micro-CT imaging 167
Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice 165
Combining Stem Cells and Exon-Skipping and Approch to Treat Muscular Dystrophies 164
Differential Activation of CD20-related Signaling Pathways Results in distinct differentiation behaviour of normal and DMD circulating CD133+ Stem Cells 162
CD133+ Cells for the Treatment of Degenerative Diseases : update and perspectives 162
Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies 158
Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases 157
Réhabilitation de la dystrophine humaine dans le modèle scid/mdx après greffe de cellules souches de patients DMD corrigées par saut d’exon 156
MiRNAs dysregulation of Single Muscle Fibers in Duchenne Muscular Dystrophy 156
Human Fetal CD133+ Muscle Cells Expressing Perycite Markers Repair Dystrophic Muscle Tissue. 156
Mesenchymal Stem Cells as Muscle Reservoir 155
Perturbation of calcium handling in CD133+ stem cells isolated from DMD blood 154
Abundance of Circulating Progenitors with Myo-Endothelial Potential Correlates with a Mild Phenotype in Patients Affected by Duchnne Muscular Dystrophy 154
Stem cell-mediated exon skipping of the dystrophin gene by the bystander effect 150
Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice 148
Cell replacement therapy in neuromuscular and neurodegenerative diseases 146
Stem cell therapy of muscular dystrophies using exon skipping approach in GRMD dogs 145
Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle 143
Flvcr1a deficiency promotes heme-based energy metabolism dysfunction in skeletal muscle 139
Perturbation of calcium handling in CD133+ stem cells isolated from DMD blood 138
Ex vivo expansion of human circulating myogenic progenitors on cluster-assembled nanostructured TiO2 138
Proliferation and clonal Characterization of Human Muscle Derived CD133+ Stem Cell Define an Intrinsic Heterogeneity 138
MicroRNA-206 is Upregulated in an Animal Model of Duchenne Muscular Dystrophy 136
Exon-Skipping of Dysferlin in CD133+ Stem Cells Isolated from normal and patient affected with Dysferlinopathies 135
MiRNAs Dysregulation of Single muscle fibers in Duchenne Muscular Dystrophy 134
Proliferation and Clonal Characterization of Human muscle Derived CD 133+ stem cell Define an Heterogeneity 133
Advancing Biomarker Discovery and Therapeutic Targets in Duchenne Muscular Dystrophy: A Comprehensive Review 129
Improvement of endurance of DMD animal model using natural polyphenols 129
Clinical applications of mesenchymal stem cells in chronic diseases 124
Full-Length Dysferlin Expression Driven by Engineered Human Dystrophic Blood-Derived CD133+ Stem Cells 124
Difference in Myogenic properties of the human blood-derived stem cells subpopulation isolated from normal and dystrophic tissues 121
Exon-skipping of dysferlin in CD133+ stem cells isolated from normal and patient affected with dysferlinopathies 117
Duchenne muscular dystrophy : isolation of CD133-expressing myogenic progenitors from blood and muscle of DMD patients 117
Combining stem cells and exon skipping strategy to treat dystrophic GRMD dogs 115
Novel insight into stem cell trafficking in dystrophic muscles 113
The immune system in duchenne muscular dystrophy pathogenesis 113
Autologous transplantation of stem cells in DMD 109
Combining Stem Cells and Exon Skipping Strategy to Treat Muscular Dystrophy 94
Stem Cell Therapy for Neuromuscular Diseases 93
Combining Stem Cells and Exon Skipping Strategy to Treat Muscular Dystrophy 86
Micro-CT technique for three-dimensional visualization of human stem cells 82
Totale 17.941
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.423
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.423
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202151 0 0 0 0 0 0 0 0 0 0 0 51
2021/20221.157 98 59 31 65 55 79 91 42 178 75 120 264
2022/20231.781 241 179 145 192 195 285 70 136 216 18 64 40
2023/2024966 38 73 44 73 300 56 46 42 10 61 90 133
2024/20252.626 98 198 64 332 206 92 158 268 118 278 205 609
2025/20265.015 517 306 461 382 448 333 661 243 504 372 458 330
Totale 17.941